AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

What this study is about

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female (sex at birth)
• Age 18 years or above at the time of signing the informed consent
• Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence [KL] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg
• Symptomatic knee OA with first appearance of pain in the target knee > 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days
• Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)/day is allowed as rescue medication up until 24 hours before those visits)

🚫 You may not be able to join if…

• Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
• History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
• Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening
• Any joint prosthesis or joint replacement in target knee
• Arthroscopy or injections into target knee within the last 90 days prior to screening
• Any other joint disease in target knee including gout and pseudogout

Where this trial is running

• Neighborhood Healthcare, Escondido, California, United States
• First Valley Medical Group, Lancaster, California, United States
• Desert Oasis Healthcare, Palm Springs, California, United States
• Chase Medical Research LLC, Waterbury, Connecticut, United States
• Westside Center For Clinical Research, Jacksonville, Florida, United States
• Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States
• Advanced Res for Health Improve, Naples, Florida, United States
• Clinical Investigation Spec Gurnee, Gurnee, Illinois, United States
• Evanston Premier Hlthcr Res, Skokie, Illinois, United States
• Monroe Biomedical Research, LLC, Louisville, Kentucky, United States
• Arcturus Healthcare, PLC., Troy, Michigan, United States
• Clinvest Research, Springfield, Missouri, United States

+ 69 more sites.

Who to contact

Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07509307.